{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T13:24:55Z","timestamp":1767705895438},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mod Rheumatol"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1007\/s10165-011-0458-z","type":"journal-article","created":{"date-parts":[[2011,4,28]],"date-time":"2011-04-28T17:15:55Z","timestamp":1304010955000},"page":"621-627","source":"Crossref","is-referenced-by-count":24,"title":["Past hepatitis B virus infection in rheumatoid arthritis patients receiving biological and\/or nonbiological disease-modifying antirheumatic drugs"],"prefix":"10.1093","volume":"21","author":[{"given":"Shunsuke","family":"Mori","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2011,4,29]]},"reference":[{"key":"458_CR1","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/art.23721","volume":"59","author":"KG Saag","year":"2008","unstructured":"Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008;59:762\u201384.","journal-title":"Arthritis Rheum"},{"key":"458_CR2","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1136\/ard.2009.126532","volume":"69","author":"JS Smolen","year":"2010","unstructured":"Smolen JS, Landewe R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010;69:964\u201375.","journal-title":"Ann Rheum Dis"},{"key":"458_CR3","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/BOR.0b013e32832c792d","volume":"21","author":"N Haroon","year":"2009","unstructured":"Haroon N, Inman RD. Infectious complications of biological therapy. Curr Opin Rheumatol. 2009;21:397\u2013403.","journal-title":"Curr Opin Rheumatol"},{"key":"458_CR4","unstructured":"Saketkoo LA, Espinoza LR. Impact of biologic agents on infectious diseases. Infect Dis Clin N Am. 2006;20:931\u201361, viii."},{"key":"458_CR5","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.3899\/jrheum.091294","volume":"37","author":"S Mori","year":"2010","unstructured":"Mori S, Cho I, Sugimoto M. A cluster of Pneumocystis jirovecii infection among outpatients with rheumatoid arthritis. J Rheumatol. 2010;37:1547\u20138.","journal-title":"J Rheumatol"},{"key":"458_CR6","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/BOR.0b013e3282f05b63","volume":"19","author":"D Vassilopoulos","year":"2007","unstructured":"Vassilopoulos D, Calabrese LH. Risks of immunosuppressive therapies including biologic agents in patients with rheumatic diseases and co-existing chronic viral infections. Curr Opin Rheumatol. 2007;19:619\u201325.","journal-title":"Curr Opin Rheumatol"},{"key":"458_CR7","doi-asserted-by":"crossref","first-page":"S156","DOI":"10.1002\/hep.22945","volume":"49","author":"JH Hoofnagle","year":"2009","unstructured":"Hoofnagle JH. Reactivation of hepatitis B. Hepatology. 2009;49:S156\u201365.","journal-title":"Hepatology"},{"key":"458_CR8","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1136\/ard.2005.043257","volume":"65","author":"LH Calabrese","year":"2006","unstructured":"Calabrese LH, Zein NN, Vassilopoulos D. Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies. Ann Rheum Dis. 2006;65:983\u20139.","journal-title":"Ann Rheum Dis"},{"key":"458_CR9","first-page":"11","volume":"2","author":"BJ McMahon","year":"2010","unstructured":"McMahon BJ. Recent advances in managing hepatitis B. F1000 Med Rep. 2010;2:11.","journal-title":"F1000 Med Rep"},{"key":"458_CR10","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.dld.2006.12.017","volume":"39","author":"A Marzano","year":"2007","unstructured":"Marzano A, Angelucci E, Andreone P, Brunetto M, Bruno R, Burra P, et al. Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liver Dis. 2007;39:397\u2013408.","journal-title":"Dig Liver Dis"},{"key":"458_CR11","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1111\/j.1445-5994.2007.01479.x","volume":"37","author":"JS Lubel","year":"2007","unstructured":"Lubel JS, Testro AG, Angus PW. Hepatitis B virus reactivation following immunosuppressive therapy: guidelines for prevention and management. Intern Med J. 2007;37:705\u201312.","journal-title":"Intern Med J"},{"key":"458_CR12","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1002\/acr.20209","volume":"62","author":"JG Stine","year":"2010","unstructured":"Stine JG, Khokhar OS, Charalambopoulos J, Shanmugam VK, Lewis JH. Rheumatologists\u2019 awareness of and screening practices for hepatitis B virus infection prior to initiating immunomodulatory therapy. Arthritis Care Res (Hoboken). 2010;62:704\u201311.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"458_CR13","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/acr.20167","volume":"62","author":"J Yazdany","year":"2010","unstructured":"Yazdany J, Calabrese L. Preventing hepatitis B reactivation in immunosuppressed patients: is it time to revisit the guidelines? Arthritis Care Res (Hoboken). 2010;62:585\u20139.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"458_CR14","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jhep.2006.10.007","volume":"46","author":"G Raimondo","year":"2007","unstructured":"Raimondo G, Pollicino T, Cacciola I, Squadrito G. Occult hepatitis B virus infection. J Hepatol. 2007;46:160\u201370.","journal-title":"J Hepatol"},{"key":"458_CR15","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.1007\/s10620-010-1413-0","volume":"55","author":"P Schmeltzer","year":"2010","unstructured":"Schmeltzer P, Sherman KE. Occult hepatitis B: clinical implications and treatment decisions. Dig Dis Sci. 2010;55:3328\u201335.","journal-title":"Dig Dis Sci"},{"key":"458_CR16","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S1473-3099(02)00345-6","volume":"2","author":"M Torbenson","year":"2002","unstructured":"Torbenson M, Thomas DL. Occult hepatitis B. Lancet Infect Dis. 2002;2:479\u201386.","journal-title":"Lancet Infect Dis"},{"key":"458_CR17","doi-asserted-by":"crossref","first-page":"346","DOI":"10.3899\/jrheum.090436","volume":"37","author":"YJ Kim","year":"2010","unstructured":"Kim YJ, Bae SC, Sung YK, Kim TH, Jun JB, Yoo DH, et al. Possible reactivation of potential hepatitis B virus occult infection by tumor necrosis factor-alpha blocker in the treatment of rheumatic diseases. J Rheumatol. 2010;37:346\u201350.","journal-title":"J Rheumatol"},{"key":"458_CR18","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/acr.20130","volume":"62","author":"R Caporali","year":"2010","unstructured":"Caporali R, Bobbio-Pallavicini F, Atzeni F, Sakellariou G, Caprioli M, Montecucco C, et al. Safety of tumor necrosis factor alpha blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative\/anti-hepatitis B core antigen positive) with rheumatic diseases. Arthritis Care Res (Hoboken). 2010;62:749\u201354.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"458_CR19","doi-asserted-by":"crossref","first-page":"R179","DOI":"10.1186\/ar2868","volume":"11","author":"C Charpin","year":"2009","unstructured":"Charpin C, Guis S, Colson P, Borentain P, Mattei JP, Alcaraz P, et al. Safety of TNF-blocking agents in rheumatic patients with serology suggesting past hepatitis B state: results from a cohort of 21 patients. Arthritis Res Ther. 2009;11:R179.","journal-title":"Arthritis Res Ther"},{"key":"458_CR20","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1136\/ard.2009.127233","volume":"69","author":"D Vassilopoulos","year":"2010","unstructured":"Vassilopoulos D, Apostolopoulou A, Hadziyannis E, Papatheodoridis GV, Manolakopoulos S, Koskinas J, et al. Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. Ann Rheum Dis. 2010;69:1352\u20135.","journal-title":"Ann Rheum Dis"},{"key":"458_CR21","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s10165-010-0337-z","volume":"21","author":"Y Urata","year":"2011","unstructured":"Urata Y, Uesato R, Tanaka D, Kowatari K, Nitobe T, Nakamura Y, et al. Prevalence of reactivation of hepatitis B virus replication in rheumatoid arthritis patients. Mod Rheumatol. 2011;21:16\u201323.","journal-title":"Mod Rheumatol"},{"key":"458_CR22","unstructured":"Tamori A, Koike T, Goto H, Wakitani S, Tada M, Morikawa H et al. Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts. J Gastroenterol. (in press)."},{"key":"458_CR23","unstructured":"Raftery G, Griffiths B, Kay L, Kane D. Chronic viral hepatitis and TNF-alpha blockade. Rheumatology (Oxford). 2007;46:1381 (author reply 1381-2)."},{"key":"458_CR24","first-page":"888","volume":"25","author":"GY Gwak","year":"2007","unstructured":"Gwak GY, Koh KC, Kim HY. Fatal hepatic failure associated with hepatitis B virus reactivation in a hepatitis B surface antigen-negative patient with rheumatoid arthritis receiving low dose methotrexate. Clin Exp Rheumatol. 2007;25:888\u20139.","journal-title":"Clin Exp Rheumatol"},{"key":"458_CR25","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/ibd.20035","volume":"13","author":"S Madonia","year":"2007","unstructured":"Madonia S, Orlando A, Scimeca D, Olivo M, Rossi F, Cottone M. Occult hepatitis B and infliximab-induced HBV reactivation. Inflamm Bowel Dis. 2007;13:508\u20139.","journal-title":"Inflamm Bowel Dis"},{"key":"458_CR26","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1111\/j.1478-3231.2007.01665.x","volume":"28","author":"PM Montiel","year":"2008","unstructured":"Montiel PM, Solis JA, Chirinos JA, a Casis B, Sanchez F, Rodriguez S. Hepatitis B virus reactivation during therapy with etanercept in an HBsAg-negative and anti-HBs-positive patient. Liver Int. 2008;28:718\u201320.","journal-title":"Liver Int"},{"key":"458_CR27","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.jbspin.2008.11.005","volume":"76","author":"D Wendling","year":"2009","unstructured":"Wendling D, Di Martino V, Prati C, Toussirot E, Herbein G. Spondyloarthropathy and chronic B hepatitis Effect of anti-TNF therapy. Joint Bone Spine. 2009;76:308\u201311.","journal-title":"Joint Bone Spine"},{"key":"458_CR28","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.3899\/jrheum.081246","volume":"36","author":"S Zingarelli","year":"2009","unstructured":"Zingarelli S, Frassi M, Bazzani C, Scarsi M, Puoti M, Airo P. Use of tumor necrosis factor-alpha-blocking agents in hepatitis B virus-positive patients: reports of 3 cases and review of the literature. J Rheumatol. 2009;36:1188\u201394.","journal-title":"J Rheumatol"},{"key":"458_CR29","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s10067-010-1523-2","volume":"29","author":"MB Carroll","year":"2010","unstructured":"Carroll MB, Forgione MA. Use of tumor necrosis factor alpha inhibitors in hepatitis B surface antigen-positive patients: a literature review and potential mechanisms of action. Clin Rheumatol. 2010;29:1021\u20139.","journal-title":"Clin Rheumatol"},{"key":"458_CR30","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1111\/j.1440-1746.2006.04559.x","volume":"21","author":"DM Nathan","year":"2006","unstructured":"Nathan DM, Angus PW, Gibson PR. Hepatitis B and C virus infections and anti-tumor necrosis factor-alpha therapy: guidelines for clinical approach. J Gastroenterol Hepatol. 2006;21:1366\u201371.","journal-title":"J Gastroenterol Hepatol"},{"key":"458_CR31","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/hep.23327","volume":"51","author":"TT Chang","year":"2010","unstructured":"Chang TT, Lai CL, Kew Yoon S, Lee SS, Coelho HS, Carrilho FJ, et al. Entecavir treatment for up to 5\u00a0years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology. 2010;51:422\u201330.","journal-title":"Hepatology"},{"key":"458_CR32","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1002\/hep.22841","volume":"49","author":"DJ Tenney","year":"2009","unstructured":"Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5\u00a0years of therapy. Hepatology. 2009;49:1503\u201314.","journal-title":"Hepatology"},{"key":"458_CR33","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1586\/eri.09.75","volume":"7","author":"SA Gonzalez","year":"2009","unstructured":"Gonzalez SA, Keeffe EB. Entecavir for the long-term treatment of chronic hepatitis B. Expert Rev Anti Infect Ther. 2009;7:1053\u201362.","journal-title":"Expert Rev Anti Infect Ther"},{"key":"458_CR34","doi-asserted-by":"crossref","first-page":"e52","DOI":"10.1086\/590968","volume":"47","author":"T Umemura","year":"2008","unstructured":"Umemura T, Tanaka E, Kiyosawa K, Kumada H. Mortality secondary to fulminant hepatic failure in patients with prior resolution of hepatitis B virus infection in Japan. Clin Infect Dis. 2008;47:e52\u20136.","journal-title":"Clin Infect Dis"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s10165-011-0458-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T16:27:43Z","timestamp":1646843263000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10165-011-0458-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4,29]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["458"],"URL":"https:\/\/doi.org\/10.1007\/s10165-011-0458-z","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,4,29]]}}}